CytoDyn (CYDY) Proxy Filing summary

Executive summary

• Leronlimab is advancing as a novel treatment in oncology, with promising preclinical and clinical data supporting its use in solid tumors, especially metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC).

• New Chief Financial Officer Robert E. Hoffman has joined, bringing expertise in capital markets and strategic planning to support growth and execution.

• Recent data presented at ESMO highlight leronlimab's ability to induce PD-L1 expression, potentially expanding eligibility for immune checkpoint inhibitor (ICI) therapies.

• Expanded access protocols and new clinical trials are being launched, including a Phase II proof-of-concept study for PD-L1-negative mTNBC patients and an investigator-initiated glioblastoma study.

• SEC and DOJ investigations have concluded with no further action required, reflecting strong compliance and governance.

Voting matters and shareholder proposals

• Shareholders are encouraged to support ongoing initiatives and to communicate through official channels to avoid hindering progress with third parties.

Board of directors and corporate governance

• Leadership has been strengthened with the appointment of a new CFO, enhancing financial oversight and strategic planning.

• An oncology advisory board has been established to guide clinical and regulatory strategy.